Data to be shared during an ObesityWeek press conference include four of seven presentations supporting CONTRAVE and its utility in helping people lose weight BRENTWOOD, Tenn., Nov. 4, 2025 ...

Program ensures continued access to treatment for patients enrolled in the Federal Employee & Retirees Health Plan (FEP) BRENTWOOD, Tenn., Oct. 23, 2025 /PRNewswire/ -- Currax Pharmaceuticals LLC, a ...

Currax Pharmaceuticals is bolstering its direct-to-consumer push, including the expansion of one campaign and the launch of another that'll partner with patients to pitch its obesity treatment as a ...

If you don't like the high prices that can come with popular weight-loss drugs like Ozempic-or the needle pokes they require-we have good news. A little-known oral diet pill called Contrave is ...

The approval of this second site enhances production capacity, confirming continued patient access to CONTRAVE while reinforcing the company's broader commitment to obesity research and treatment.

Orexigen® Therapeutics, Inc. OREX today announced that the Light Study, a long-term research study of Contrave® (naltrexone SR/bupropion SR), a new, investigational drug being evaluated for weight ...

Orexigen Therapeutics, Inc. (NASDAQ: OREX) may have jumped the gun in reporting that its anti-obesity drug Contrave offers unexpected benefits to cardiovascular patients. The Miami-based company ...

BRENTWOOD, Tenn., March 20, 2025 /PRNewswire/ -- Currax Pharmaceuticals LLC ("Currax"), a specialty pharmaceutical company and manufacturer of the #1 branded oral weight loss medication CONTRAVE ® ...